UNITE Glioblastoma is triggered by the strong vision that glioblastoma is treatable. To tackle this challenge, the research strategy is driven by innovation, strong collaboration and a focus on clinical implementation.
The UNITE research program focuses on unraveling mechanisms of intrinsic resistance (Focus A) and mechanisms of resistance conferred by the microenvironment (Focus B). Utilizing state-of the art technological innovation, novel high-throughput technologies, preclinical models, and analytical tools will be developed, applied, and shared as a resource within the initiative (Focus C). Integrated cores for tissue material, including a core set of jointly used patient-derived models, and integrative data analysis (Focus D) support work package leaders to efficiently use personal multi-dimensional-omic data for therapy guidance and precision medicine. For 100 selected tissue samples – the UNITE Core Collection – a uniform, integrated data matrix, consisting of multi-omics, imaging and clinical data, will be generated to understand initiation, progression and therapy resistance of glioblastomas at a molecular basis of patient-derived tissues. By drawing a multidimensional map of therapy resistance, UNITE aims to develop concepts to predict and monitor treatment response and failure, and ultimately, to invent novel (combination) therapies for glioblastoma patients.